17,785 Shares in MiMedx Group, Inc. (NASDAQ:MDXG) Bought by Palumbo Wealth Management LLC

Palumbo Wealth Management LLC bought a new stake in MiMedx Group, Inc. (NASDAQ:MDXG) during the fourth quarter, HoldingsChannel.com reports. The firm bought 17,785 shares of the company’s stock, valued at approximately $171,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MDXG. Van ECK Associates Corp acquired a new stake in shares of MiMedx Group in the 4th quarter valued at approximately $40,000. Blue Trust Inc. acquired a new stake in MiMedx Group in the third quarter valued at approximately $30,000. Point72 DIFC Ltd grew its stake in shares of MiMedx Group by 127.6% during the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock worth $45,000 after buying an additional 4,275 shares during the last quarter. Savant Capital LLC bought a new stake in shares of MiMedx Group during the fourth quarter worth $100,000. Finally, Entropy Technologies LP acquired a new position in shares of MiMedx Group during the third quarter worth $64,000. Institutional investors own 79.15% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com lowered MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $12.00.

MiMedx Group Trading Up 1.4 %

Shares of NASDAQ MDXG opened at $8.40 on Friday. The firm has a 50 day moving average price of $8.98 and a two-hundred day moving average price of $7.60. The stock has a market cap of $1.23 billion, a P/E ratio of 15.27 and a beta of 1.94. MiMedx Group, Inc. has a 52-week low of $5.47 and a 52-week high of $10.14. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.